Unknown

Dataset Information

0

Novel Therapies in Development for Metastatic Colorectal Cancer.

ABSTRACT: Colorectal cancer (CRC) is the second most common cause of cancer mortality in the United States. Despite advances in therapy, metastatic CRC remains lethal, and further improvements in therapy are needed. Growing understanding of cancer biology, particularly in growth factor signaling, angiogenesis, and cancer immunology, has translated into many novel therapies under investigation. Patients are increasingly selected for clinical trials rationally on the basis of integral biomarkers. This review discusses several promising agents in development for metastatic CRC.

SUBMITTER: Lee MS 

PROVIDER: S-EPMC4812839 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel Therapies in Development for Metastatic Colorectal Cancer.

Lee Michael S MS   Kopetz Scott S  

Gastrointestinal cancer research : GCR 20140901 4 Suppl 1

Colorectal cancer (CRC) is the second most common cause of cancer mortality in the United States. Despite advances in therapy, metastatic CRC remains lethal, and further improvements in therapy are needed. Growing understanding of cancer biology, particularly in growth factor signaling, angiogenesis, and cancer immunology, has translated into many novel therapies under investigation. Patients are increasingly selected for clinical trials rationally on the basis of integral biomarkers. This revie  ...[more]

Similar Datasets

Unknown Integrating anti-EGFR therapies in metastatic colorectal cancer.
| S-EPMC3712294 | biostudies-other
Unknown Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies.
| S-EPMC8307556 | biostudies-literature
Unknown Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer.
| S-EPMC3425342 | biostudies-other
Unknown Novel targeted therapies for metastatic breast cancer.
| S-EPMC7396776 | biostudies-literature
Unknown Novel therapies for metastatic castrate-resistant prostate cancer.
| S-EPMC4176261 | biostudies-literature
Unknown Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).
| S-EPMC6850201 | biostudies-literature
Unknown Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives.
| S-EPMC3848143 | biostudies-literature
Unknown Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.
| S-EPMC5635852 | biostudies-literature
Unknown Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients.
| S-EPMC7463997 | biostudies-literature
Unknown Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
| S-EPMC3336830 | biostudies-other